From 20 October, a free online platform will allow registrants attending the digital Global Generics & Biosimilars Awards 2020 to participate in two weeks of dedicated networking activities ahead of the ceremony on 3 November.

In this podcast discussion, Generics Bulletin editor David Wallace talks to Duncan Emerton, director of Custom Intelligence and Analytics for Informa Pharma Intelligence, about the UK's new licensing procedure for biosimilars.

Roche entered the year with a projected hit to revenues from multi-source biosimilar competition to its three leading biologics. However, the number was increased at the half-year mark and could be set to ratchet up further, according to management.

Australia’s Therapeutic Goods Administration has set out proposals for a change to early-notification requirements for generic and biosimilar sponsors.

Alexion Pharmaceuticals’ Soliris (eculizumab) blockbuster represents a significant opportunity for biosimilar sponsors around the globe. Ahead of anticipated US competition in 2025, the originator has added a new formulation for next-generation product Ultomiris (ravulizumab-cwvz).

German biosimilars firm Formycon has raised tens of millions of euros through an issue of new shares, with the cash earmarked for its burgeoning pipeline of wholly-owned biosimilars, including a Lucentis (ranibizumab) candidate being developed with Coherus.